The overall incidence rate of pneumonitis varies from 2.5% to 5% with PD-1/PD-L1 inhibitors to 7%–10% with a dual combination of Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)/PD-1 inhibitors (76). The gene discussed is CD274; the disease is pneumonitis.